acetaminophen has been researched along with Rhinitis in 26 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Rhinitis: Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acetaminophen is frequently prescribed for treating patients with the common cold, but there is little evidence as to whether it is effective." | 8.89 | Acetaminophen (paracetamol) for the common cold in adults. ( Dong, BR; Li, S; Lin, X; Wu, T; Yang, M; Yue, J, 2013) |
| "There is epidemiological evidence that the use of acetaminophen may increase the risk of developing asthma." | 7.77 | Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International Study of Asthma and Allergies in Childhood Phase Three. ( Beasley, RW; Clayton, TO; Crane, J; Lai, CK; Montefort, SR; Mutius, Ev; Stewart, AW, 2011) |
| " We sought to evaluate the effectiveness and safety of over the counter dosing of ibuprofen on pain and bleeding rates following ESS." | 5.56 | Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. ( Davis, GE; Humphreys, IM; Miller, C, 2020) |
| "This study clearly showed the efficacy of a short course of oral prednisone (3 days), versus a placebo, in the treatment of the functional signs of acute maxillary rhinosinusitis with severe pain in adults in addition to an appropriate antibiotic treatment." | 5.11 | [Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days]. ( Bordure, P; Coriat, F; Deslandes, B; Desmonts-Gohler, C; Dubreuil, C; Gehanno, P; Gilain, L; Jankowski, R; Klossek, JM; Serrano, E; Stoll, D, 2004) |
| "Acetaminophen is frequently prescribed for treating patients with the common cold, but there is little evidence as to whether it is effective." | 4.89 | Acetaminophen (paracetamol) for the common cold in adults. ( Dong, BR; Li, S; Lin, X; Wu, T; Yang, M; Yue, J, 2013) |
| "Relevant articles in the medical literature were derived from searching the MEDLINE database with key terms aspirin-sensitive asthma, cyclo-oxygenase enzymes 1 and 2." | 4.81 | Sensitivity to nonsteroidal anti-inflammatory drugs. ( Namazy, JA; Simon, RA, 2002) |
| "There is epidemiological evidence that the use of acetaminophen may increase the risk of developing asthma." | 3.77 | Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International Study of Asthma and Allergies in Childhood Phase Three. ( Beasley, RW; Clayton, TO; Crane, J; Lai, CK; Montefort, SR; Mutius, Ev; Stewart, AW, 2011) |
| "The primary outcome was postoperative pain measured by visual analog scale (VAS) scores up to 24 hours after surgery by blinded observers." | 2.84 | Analgesic Effects of Intravenous Acetaminophen vs Placebo for Endoscopic Sinus Surgery and Postoperative Pain: A Randomized Clinical Trial. ( Ashoori, F; Cai, C; Cattano, D; Citardi, MJ; Fakhri, S; Kain, JJ; Lam, K; Luong, A; Tyler, MA, 2017) |
| "We sought to study postoperative pain after endoscopic sinus surgery and to evaluate the efficacy of dexamethasone sodium phosphate in reducing pain and rescue analgesic requirements." | 2.75 | Role of dexamethasone in reducing pain after endoscopic sinus surgery in adults: a double-blind prospective randomized trial. ( Al-Qudah, M; Rashdan, Y, 2010) |
| " We sought to evaluate the effectiveness and safety of over the counter dosing of ibuprofen on pain and bleeding rates following ESS." | 1.56 | Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. ( Davis, GE; Humphreys, IM; Miller, C, 2020) |
| "Rhinitis was associated with a greater number of episodes of night cough in adolescents with asthma." | 1.46 | Prevalence of asthma and allergies in 13-14-year-old adolescents from Luanda, Angola. ( Arrais, M; Gama, JMR; Lulua, O; Quifica, F; Rosado-Pinto, J; Taborda-Barata, L, 2017) |
| " Following implant surgery, postoperative pain was rated moderate or severe in 25/28 patients (89 percent), requiring prn analgesic dosing for up to 3 days in 14/25 individuals (56 percent)." | 1.39 | Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac. ( Bockow, R; Bodner, L; Hersh, EV; Hutcheson, M; Korostoff, J; Pinto, A; Secreto, SA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, C | 1 |
| Humphreys, IM | 1 |
| Davis, GE | 1 |
| Ayoub, NF | 1 |
| Choby, G | 1 |
| Turner, JH | 1 |
| Abuzeid, WM | 1 |
| Raviv, JR | 1 |
| Thamboo, A | 1 |
| Ma, Y | 1 |
| Chandra, RK | 1 |
| Chowdhury, NI | 1 |
| Stokken, JK | 1 |
| O'Brien, EK | 1 |
| Shah, S | 1 |
| Akbar, N | 1 |
| Roozdar, P | 1 |
| Nayak, JV | 1 |
| Patel, ZM | 1 |
| Hwang, PH | 1 |
| Arrais, M | 1 |
| Lulua, O | 1 |
| Quifica, F | 1 |
| Rosado-Pinto, J | 1 |
| Gama, JMR | 1 |
| Taborda-Barata, L | 1 |
| Tyler, MA | 1 |
| Lam, K | 1 |
| Ashoori, F | 1 |
| Cai, C | 1 |
| Kain, JJ | 1 |
| Fakhri, S | 1 |
| Citardi, MJ | 1 |
| Cattano, D | 1 |
| Luong, A | 1 |
| Lipiec, A | 1 |
| Wawrzyniak, ZM | 1 |
| Sybilski, AJ | 1 |
| Samolińska-Zawisza, U | 1 |
| Krzych-Fałta, E | 1 |
| Piekarska, B | 1 |
| Dulny, G | 1 |
| Stankiewicz-Choroszucha, B | 1 |
| Raciborski, F | 1 |
| Samoliński, B | 1 |
| Umstattd, LA | 1 |
| Dooley, LM | 1 |
| Li, S | 1 |
| Yue, J | 1 |
| Dong, BR | 1 |
| Yang, M | 1 |
| Lin, X | 1 |
| Wu, T | 1 |
| Muc, M | 1 |
| Padez, C | 1 |
| Pinto, AM | 1 |
| Bockow, R | 1 |
| Korostoff, J | 1 |
| Pinto, A | 1 |
| Hutcheson, M | 1 |
| Secreto, SA | 1 |
| Bodner, L | 1 |
| Hersh, EV | 1 |
| Beasley, R | 1 |
| Clayton, T | 1 |
| Crane, J | 2 |
| von Mutius, E | 1 |
| Lai, CK | 2 |
| Montefort, S | 1 |
| Stewart, A | 1 |
| Al-Qudah, M | 1 |
| Rashdan, Y | 1 |
| Garcia-Marcos, L | 1 |
| González-Díaz, C | 1 |
| Garvajal-Urueña, I | 1 |
| Pac-Sa, MR | 1 |
| Busquets-Monge, RM | 1 |
| Suárez-Varela, MM | 1 |
| Batlles-Garrido, J | 1 |
| Blanco-Quirós, A | 1 |
| Varela, AL | 1 |
| García-Hernández, G | 1 |
| Aguinaga-Ontoso, I | 1 |
| Beasley, RW | 1 |
| Clayton, TO | 1 |
| Montefort, SR | 1 |
| Mutius, Ev | 1 |
| Stewart, AW | 1 |
| Kurukulaaratchy, RJ | 2 |
| Raza, A | 2 |
| Scott, M | 1 |
| Williams, P | 1 |
| Ewart, S | 2 |
| Matthews, S | 1 |
| Roberts, G | 2 |
| Hasan Arshad, S | 1 |
| Grundy, JD | 1 |
| Clayton, CB | 1 |
| Mitchell, FA | 1 |
| Sadeghnejad, A | 1 |
| Arshad, SH | 1 |
| Namazy, JA | 1 |
| Simon, RA | 1 |
| FICHSEL, H | 1 |
| Klossek, JM | 1 |
| Desmonts-Gohler, C | 1 |
| Deslandes, B | 1 |
| Coriat, F | 1 |
| Bordure, P | 1 |
| Dubreuil, C | 1 |
| Gehanno, P | 1 |
| Gilain, L | 1 |
| Jankowski, R | 1 |
| Serrano, E | 1 |
| Stoll, D | 1 |
| Cohet, C | 1 |
| Cheng, S | 1 |
| MacDonald, C | 1 |
| Baker, M | 1 |
| Foliaki, S | 1 |
| Huntington, N | 1 |
| Douwes, J | 1 |
| Pearce, N | 1 |
| Rallis, E | 1 |
| Balatsouras, DG | 1 |
| Kouskoukis, C | 1 |
| Verros, C | 1 |
| Homsioglou, E | 1 |
| Barragán-Meijueiro, MM | 1 |
| Morfín-Maciel, B | 1 |
| Nava-Ocampo, AA | 1 |
| Ben Salem, C | 1 |
| Slim, R | 1 |
| Denguezli, M | 1 |
| Sriha, B | 1 |
| Hmouda, H | 1 |
| Bouraoui, K | 1 |
| Pastorello, EA | 1 |
| Zara, C | 1 |
| Riario-Sforza, GG | 1 |
| Pravettoni, V | 1 |
| Incorvaia, C | 1 |
| Cüppers, H | 1 |
| Froidevaux, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-institutional, Randomized Controlled Trial Assessing Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery[NCT03783702] | Phase 4 | 118 participants (Actual) | Interventional | 2019-04-04 | Completed | ||
| A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain[NCT01608308] | 62 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Single-dose and Multi-dose Open-label Pilot Trial of the Analgesic Efficacy and Tolerability of Intranasal Ketorolac Tromethamine (SPRIX®) in Dental Implant Surgery Patients With Postoperative Pain.[NCT01490931] | Phase 4 | 28 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Demonstration of OTC Naproxen Sodium's (Aleve's) Anti-inflammatory Action in Dental Implant Surgery Patients[NCT04694300] | Phase 4 | 32 participants (Actual) | Interventional | 2021-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 2.8 |
| Control Group | 2.9 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 2.5 |
| Control Group | 2.3 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.9 |
| Control Group | 2.1 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.5 |
| Control Group | 1.9 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.7 |
| Control Group | 1.6 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.5 |
| Control Group | 1.4 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.3 |
| Control Group | 1.4 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: BPI score will be collected at the preoperative visit
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.6 |
| Control Group | 1.0 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score was collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 30.2 |
| Control Group | 29.4 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 27.0 |
| Control Group | 23.5 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 19.2 |
| Control Group | 22.5 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 14.1 |
| Control Group | 16.8 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 15.8 |
| Control Group | 15.0 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 13.9 |
| Control Group | 11.7 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 8.1 |
| Control Group | 10.1 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for preoperative visit (the day before surgery)
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 12.4 |
| Control Group | 8.5 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected at the preoperative visit
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 0 |
| Control Group | 0 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 36.3 |
| Control Group | 38.9 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 23.0 |
| Control Group | 21.6 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 15.9 |
| Control Group | 12.9 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 9.3 |
| Control Group | 11.8 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 10.1 |
| Control Group | 7.8 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 6.5 |
| Control Group | 6.6 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 4.6 |
| Control Group | 5.4 |
Patients kept a daily medication log and reported the number of doses consumed per day (650mg acetaminophen, 600mg ibuprofen, 5mg oxycodone). The mean number of medication doses per day was calculated for each treatment group. (NCT03783702)
Timeframe: Postoperative day 1 to 7
| Intervention | Average number of medication doses/day (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxycodone POD1 | Oxycodone POD2 | Oxycodone POD3 | Oxycodone POD4 | Oxycodone POD5 | Oxycodone POD6 | Oxycodone POD7 | Acetaminophen POD1 | Acetaminophen POD2 | Acetaminophen POD3 | Acetaminophen POD4 | Acetaminophen POD5 | Acetaminophen POD6 | Acetaminophen POD7 | Ibuprofen POD1 | Ibuprofen POD2 | Ibuprofen POD3 | Ibuprofen POD4 | Ibuprofen POD5 | Ibuprofen POD6 | Ibuprofen POD7 | |
| Control Group | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 | 0.1 | 0 | 2.1 | 1.9 | 1.6 | 1.5 | 1.3 | 1.1 | 0.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Experimental Group | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 2.0 | 1.8 | 1.3 | 1.0 | 0.9 | 0.9 | 0.6 | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | 0.3 | 0.2 |
Post-operative nausea will be monitored and measured through direct observation and nursing clinical record (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | participants (Number) |
|---|---|
| IV Acetaminophen | 13 |
| Control | 10 |
Number of participants who received intraoperative supplemental fentanyl. The decision to administer fentanyl is based on hemodynamic changes, such as increasing blood pressure and heart rate. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | participants (Number) |
|---|---|
| IV Acetaminophen | 9 |
| Control | 4 |
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | mmHg (Mean) |
|---|---|
| IV Acetaminophen | 75 |
| Control | 78.3 |
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | beats per minute (Mean) |
|---|---|
| IV Acetaminophen | 76.3 |
| Control | 80 |
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | breaths per minute (Mean) |
|---|---|
| IV Acetaminophen | 17.4 |
| Control | 17.2 |
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | mmHg (Mean) |
|---|---|
| IV Acetaminophen | 133 |
| Control | 144 |
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | Fahrenheit (Mean) |
|---|---|
| IV Acetaminophen | 97.1 |
| Control | 97.4 |
The total amount of morphine utilized in Postoperative Acute Care Unit (PACU) will be recorded. One dose is a 1mg bolus of morphine. (NCT01608308)
Timeframe: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
| Intervention | doses (Median) |
|---|---|
| IV Acetaminophen | 1.5 |
| Control | 2.5 |
VAS is a validated, self-reported data sheet assessing average pain intensity. Possible scores range from 0 (no pain) to 10 (highest level of pain). (NCT01608308)
Timeframe: 15 minutes and 120 minutes Post-Operatively
| Intervention | units on a scale (Median) | |
|---|---|---|
| 15 minutes (n=24, 26) | 120 minutes (n=7, 11) | |
| Control | 0 | 2 |
| IV Acetaminophen | 0 | 0 |
(NCT01490931)
Timeframe: 2 Hours
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 9.1 |
Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale (NCT01490931)
Timeframe: 20 minutes post dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 14.3 |
(NCT01490931)
Timeframe: 3 hours post-dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 9.6 |
(NCT01490931)
Timeframe: 4 Hours post-dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 10.0 |
VAS pain intensity score at 40 minutes post-dose (NCT01490931)
Timeframe: 40 minutes post dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 10.1 |
(NCT01490931)
Timeframe: 5 Hours post-dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 16.2 |
(NCT01490931)
Timeframe: 6 Hours post-dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 19.8 |
VAS pain intensity score 60 minutes after dosing. (NCT01490931)
Timeframe: 60 minutes post dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 10.6 |
(NCT01490931)
Timeframe: 90 minutes post-dose
| Intervention | millimeters (Mean) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 9.6 |
Measure obtained using recognized double-stop watch technique. Patient is asked to depress the second stop watch when pain relief is meaningful to them. Each patient decides what meaningful relief is for them. (NCT01490931)
Timeframe: At time of depressing meaningful relief stopwatch up to 6 hours.
| Intervention | seconds (Median) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 172 |
Self explanatory (NCT01490931)
Timeframe: Up to 5 days
| Intervention | days (Number) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 3 |
(NCT01490931)
Timeframe: Up to 5 hours after last suture is placed
| Intervention | percentage of participants (Number) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 89 |
Data will be obtained employing the well-described double stop watch technique (NCT01490931)
Timeframe: Censored at 6 hours
| Intervention | seconds (Median) |
|---|---|
| Ketorolac Nasal Spray 31.5 mg (SPRIX) | 86 |
2 reviews available for acetaminophen and Rhinitis
| Article | Year |
|---|---|
Acetaminophen (paracetamol) for the common cold in adults.
Topics: Acetaminophen; Adult; Common Cold; Humans; Nasal Obstruction; Randomized Controlled Trials as Topic; | 2013 |
Sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bleedin | 2002 |
4 trials available for acetaminophen and Rhinitis
| Article | Year |
|---|---|
Assessment of Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery: A Randomized Clinical Trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opi | 2021 |
Analgesic Effects of Intravenous Acetaminophen vs Placebo for Endoscopic Sinus Surgery and Postoperative Pain: A Randomized Clinical Trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Double-Blind Method; Endoscopy; Female; Humans; Infusions, | 2017 |
Role of dexamethasone in reducing pain after endoscopic sinus surgery in adults: a double-blind prospective randomized trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Chronic Disease; Dexametha | 2010 |
[Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days].
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-In | 2004 |
20 other studies available for acetaminophen and Rhinitis
| Article | Year |
|---|---|
Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Cohort St | 2020 |
Prevalence of asthma and allergies in 13-14-year-old adolescents from Luanda, Angola.
Topics: Acetaminophen; Adolescent; Angola; Asthma; Cross-Sectional Studies; Eczema; Female; Humans; Hypersen | 2017 |
The association between paracetamol use and the risk of asthma, rhinitis and eczema in the Polish population.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Asthma; Child; Eczema; Female; Humans; M | 2018 |
Tissue Necrosis and Fungal Rhinosinusitis Resulting From Intranasal Acetaminophen Use.
Topics: Acetaminophen; Administration, Intranasal; Adult; Female; Humans; Medical Illustration; Mycoses; Nas | 2020 |
Exposure to paracetamol and antibiotics in early life and elevated risk of asthma in childhood.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Asthma; Child; Cross-Sectional Studi | 2013 |
Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.
Topics: Acetaminophen; Administration, Intranasal; Adult; Analgesia, Patient-Controlled; Analgesics, Non-Nar | 2013 |
Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.
Topics: Acetaminophen; Administration, Intranasal; Adult; Analgesia, Patient-Controlled; Analgesics, Non-Nar | 2013 |
Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.
Topics: Acetaminophen; Administration, Intranasal; Adult; Analgesia, Patient-Controlled; Analgesics, Non-Nar | 2013 |
Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.
Topics: Acetaminophen; Administration, Intranasal; Adult; Analgesia, Patient-Controlled; Analgesics, Non-Nar | 2013 |
Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Asthma; Child; Conjunctivitis; Cross-Sectional | 2008 |
Best drugs for what ails you: the brands to buy--and those to skip.
Topics: Acetaminophen; Anesthetics, Local; Cetirizine; Chlorpheniramine; Common Cold; Cough; Dextromethorpha | 2009 |
Early exposure to paracetamol or to antibiotics and eczema at school age: modification by asthma and rhinoconjunctivitis.
Topics: Acetaminophen; Anti-Bacterial Agents; Asthma; Child; Conjunctivitis; Eczema; Family; Female; Humans; | 2010 |
Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International Study of Asthma and Allergies in Childhood Phase Three.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Asthma; Causality; Cohort Studies; Conjunctivit | 2011 |
Characterisation of asthma that develops during adolescence; findings from the Isle of Wight Birth Cohort.
Topics: Acetaminophen; Adolescent; Age Factors; Age of Onset; Analgesics, Non-Narcotic; Asthma; Bronchial Hy | 2012 |
What does adolescent undiagnosed wheeze represent? Findings from the Isle of Wight Cohort.
Topics: Acetaminophen; Adolescent; Antipyretics; Asthma; Child; Child, Preschool; Cohort Studies; Female; He | 2012 |
[EXPERIENCES WITH A NEW ANTIPYRETIC AND ANALGESIC IN A NEW RECTAL CAPSULE FORM].
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Bronchitis; Bronchopneumonia; Cap | 1963 |
Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood.
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Asthma; Child; Child, P | 2004 |
Drug eruptions in children with ENT infections.
Topics: Acetaminophen; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Cephalosporins; Child; Chi | 2006 |
A Mexican population-based study on exposure to paracetamol and the risk of wheezing, rhinitis, and eeczema in childhood.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Case-Control Studies; Child; Child, | 2006 |
Pseudoephedrine-induced acute generalized exanthematous pustulosis.
Topics: Acetaminophen; Adult; Drug Combinations; Drug Eruptions; Exanthema; Female; Humans; Pseudoephedrine; | 2008 |
Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Allergens; Anti-Inflammatory Agents, Non- | 1998 |
[Rhinitis and it's therapy with Co-Tylenol].
Topics: Acetaminophen; Adenoviridae Infections; Child; Environment; Humans; Phenylephrine; Rhinitis; Rhiniti | 1972 |
[The therapy of rhinitis and cold syndromes].
Topics: Acetaminophen; Common Cold; Humans; Phenylephrine; Rhinitis | 1972 |